CRDF Cardiff Oncology
Cardiff Oncology earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | -0.13 | — | — |
| Rev | $86.4K | — | — |
Insider trades
Open-market buys and sales by CRDF's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $1.1M bought by 2 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Gary W Pace DirectorBuy$1M 687,285 shares at $1.46 +51% to stakeTraded Jul 14 Filed Jul 16
-
Mani Mohindru CEOBuy$50K 34,364 shares at $1.46 +139% to stakeTraded Jul 14 Filed Jul 16
-
Mani Mohindru CEOBuy$30K 24,703 shares at $1.21 New stakeTraded Jun 18 Filed Jun 22
-
Gary W Pace DirectorBuy$37K 30,000 shares at $1.22 +2.3% to stakeTraded Jun 18 Filed Jun 22
SEC filings
Recent issuer filings from EDGAR, 24 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02,5.03,7.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| 8-K | 1.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 5.02,8.01,9.01 | Filing Doc | |
| 8-K | 1.01,5.02 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 2.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.